Home Biosimilar Antibodies Others Others Anti-CEACAM6 / CD66c (NEO-201)
For research use only. Not for use in humans.

Anti-CEACAM6 / CD66c (NEO-201)

Synonyms: CEAL， CEAM6

Anti-CEACAM6 / CD66c (NEO-201) is a humanized IgG1 monoclonal antibody that targets of CEACAM family. It enhances natural killer cell cytotoxicity against tumor cells. MW :145.48 KD.

Anti-CEACAM6 / CD66c (NEO-201)

Quality Control

Batch: A263901 Purity: 99% Protein concentration: 5.19mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Anti-CEACAM6 / CD66c (NEO-201) is a humanized IgG1 monoclonal antibody that targets of CEACAM family. It enhances natural killer cell cytotoxicity against tumor cells. MW :145.48 KD.
References

Product Details

Molecular Weight 145.48
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03476681 ACTIVE_NOT_RECRUITING Drug: NEO-201 in combination with pembrolizumab Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer Precision Biologics, Inc 2019-01-18 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-22)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.